Find Product



  • ENG
  • မြန်မာ



(60,000 IU Vitamin D3 Oral Solution)



Each 5 ml contains:

Cholecalciferol USP (as stabilized)            60000 IU

(In Nano droplet form)

In a Flavoured base                                    q.s.

Colour: Approved colour used

Appropriate overage of vitamin added



Yellow coloured, clear solution filled in amber coloured glass bottle, sweet in taste with flavoured odour.



Oral solution (In Nano droplet form) – 60000 IU


The primary constituent of NANO-D is Vitamin D3 (Cholecalciferol). This vitamin is an essential component in human body, which helps in the absorption of calcium and phosphates from the bowel. It is vital for keeping bones and teeth healthy.

NANO-D is indicated for




Pharmacodynamics Properties

Pharmacotherapeutic group: Vitamin D3, Cholecalciferol


In its biologically active form Vitamin D3 stimulates intestinal calcium absorption, incorporation of calcium into the osteoid, and release of calcium from bone tissue. In the small intestine it promotes rapid and delayed calcium uptake. The passive and active transport of phosphate is also stimulated. In the kidney, it inhibits the excretion of calcium and phosphate by promoting tubular resorption. The production of parathyroid hormone (PTH) in the parathyroids is inhibited directly by the biologically active form of Vitamin D3. PTH secretion is inhibited additionally by the increased calcium uptake in the small intestine under the influence of biologically active Vitamin D3.



Pharmacokinetic properties

The pharmacokinetics of Vitamin D3 is well known.

Absorption: Vitamin D3 is well absorbed from the gastro-intestinal tract in the presence of bile, so the administration with the major meal of the day might therefore facilitate the absorption of Vitamin D3


Distribution and biotransformation: it is hydroxylated in the liver to form 25-hydroxy-colecalciferol and then undergoes further hydroxylation in the kidney to form the active metabolite 1, 25-dihydroxycolecalciferol (calcitriol).


Elimination: The metabolites circulate in the blood bound to a specific a globulin, Vitamin D3 and its metabolites are excreted mainly in the bile and faces.


Characteristics in Specific Groups of Subjects or Patients

A 57% lower metabolic clearance rate is reported in subjects with renal impairment as compared with that of healthy volunteers. Decreased absorption and increased elimination of Vitamin D3 occurs in subjects with malabsorption. Obese subjects are less able to maintain Vitamin D3 levels with sun exposure, and are likely to require larger oral doses of Vitamin D3 to replace deficits.



Treatment of Vitamin D3 deficiency (<25 nmol/) 60,000 IU/week (I single-dose oral solution) for 6-8 weeks, followed by maintenance therapy (equivalent to 1400-2000 IU/day, such as I single-dose 60,000 IU oral solution per month) is recommended; follow-up 25(OH) D measurements should be made approximately three to four months after initiating maintenance therapy to confirm that the target level has been achieved).


Method of administration:

Patients is advised to take NANO-D preferably with meal through oral route

Administration to adults:

The single-dose oral solution should be either emptied into the mouth and swallowed orally, or emptied on to a spoon and taken orally.



The blood calcium levels should be confirmed before taking this medication.


Pseudohypoparathyroidism as the Vitamin D3 requirement may be reduced due to phases of normal Vitamin D3 sensitivity, involving the risk of prolonged overdose. Better regulatable Vitamin D3 derivatives are available for this.






Adverse reactions are listed below, by system organ class and frequency. Frequencies are defined are Uncommon (>1/1,000, €1/100) or rare (=* 1/110, 000. 1/1.000).

Metabolism and nutrition disorders

Uncommon: Hypercalcaemia and hypercalciuria

Skin and subcutaneous disorders:

Rare: pruritus, rash, and urticaria.




Interaction with Alcohol


Interaction with Medicine


Disease interactions


This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you are taking.



In pregnancy and lactation the high strength formulation is not recommended a low strength formulation should prefer


There are no or limited data for the use of colecalciferol in pregnant women. Studies in animals have shown reproductive toxicity. The recommended daily intake for pregnant women is 400 IU, however, in women who are considered to be Vitamin D3 deficient a higher dose may be required. During pregnancy women should follow the advice of their medical practitioner as their requirements may vary depending on the severity of their disease and their response to treatment Vitamin D3.


Vitamin D3 can be prescribed while the patient is breast-feeding if necessary. This supplementation do not replace the administration of Vitamin D3 in the neonate.


There is no data regarding treatment with Vitamin D3 and its effects on fertility.



Symptoms of chronic Vitamin D3 over dosage may require forced diuresis as well as administration of glucocorticoids or calcitonin.

No special antidote exits.

It is recommended to point out the symptoms of potential overdose to patients under chronic therapy with higher doses of Vitamin D3



Store below 30°C. Protect from light.


Keep medicine out of reach of children.



4 x5 ml Amber glass bottle with poly propylene cap packed in a carton along with package insert.


Primary Container

Amber glass bottle &polypropylene cap.


Secondary Container

Carton, Label, D3 Tray & package insert.


Shelf life

24 Months from the date of manufacturing.


Related Products